Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice

Clark, Richard E ORCID: 0000-0002-1261-3299 (2019) Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 14 (6). pp. 507-514.

Text
paper193 TKI stopping review FINAL 1 Aug.docx - Author Accepted Manuscript
Download (493kB)

Official URL: http://dx.doi.org/10.1007/s11899-019-00548-2

Abstract

<h4>Purpose</h4>In chronic myeloid leukaemia, tyrosine kinase inhibitor treatment is traditionally given continuously for life. However, these drugs produce excellent responses for many patients, and this is accompanied by survival that is close to normal. This has prompted studies of whether it is possible to stop treatment, thus achieving a treatment-free remission (TFR).<h4>Recent findings</h4>Most TFR studies have focussed on abrupt cessation in patients with long-standing deep remissions, but recent data suggest that more gradual treatment de-escalation may improve TFR success, and that it may be possible to extend TFR attempts to patients who are in stable major molecular response but not necessarily MR4. Further data are badly needed on TFR for patients whose remission is less than stable MR4 and on the importance of prior interferon-alpha treatment. Funding TFR trials in a disease with such an excellent outlook is an increasing challenge.

Item Type:	Article
Uncontrolled Keywords:	Chronic myeloid leukaemia, CML, Discontinuing treatment, TKI, Tyrosine kinase inhibitors
Depositing User:	Symplectic Admin
Date Deposited:	21 Nov 2019 11:47
Last Modified:	25 Jan 2024 06:20
DOI:	10.1007/s11899-019-00548-2
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3062668